Trial Profile
A phase III study to evaluate rivaroxaban in patients who have suffered an acute coronary syndrome (ACS)
Status:
Planning
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2014
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Acute coronary syndromes
- Focus Adverse reactions; Therapeutic Use
- Acronyms GEMINI 2 ACS; GEMINI ACS 2
- 05 Sep 2014 New trial record
- 29 Aug 2014 Bayer Healthcare will initiate this confirmatory GEMINI ACS 2 study if GEMINI ACS 1 study is successful.